Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Hydrochloride Liposome and Enlonstobart in Relapsed or Refractory PTCL
NCT07288814Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone and PBI-1308 in peripheral T-cell lymphoma (PTCL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Dose Limiting Toxicities at 28 days, Recommended Phase II Dose at 3 months and 1 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
mitoxantronePBI-1308
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07288814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288814.